Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

251 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies--a prospective, multi-national study.
Gardulf A, Nicolay U, Asensio O, Bernatowska E, Böck A, Carvalho BC, Granert C, Haag S, Hernández D, Kiessling P, Kus J, Pons J, Niehues T, Schmidt S, Schulze I, Borte M. Gardulf A, et al. Among authors: borte m. J Clin Immunol. 2006 Mar;26(2):177-85. doi: 10.1007/s10875-006-9002-x. Epub 2006 Apr 26. J Clin Immunol. 2006. PMID: 16758340 Clinical Trial.
Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study.
Borte M, Melamed IR, Pulka G, Pyringer B, Knutsen AP, Ochs HD, Kobayashi RH, Kobayashi AL, Gupta S, Strach M, Smits W, Pituch-Noworolska A, Moy JN. Borte M, et al. J Clin Immunol. 2017 Aug;37(6):603-612. doi: 10.1007/s10875-017-0424-4. Epub 2017 Jul 29. J Clin Immunol. 2017. PMID: 28755067 Free PMC article. Clinical Trial.
Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home.
Gardulf A, Nicolay U, Math D, Asensio O, Bernatowska E, Böck A, Costa-Carvalho BT, Granert C, Haag S, Hernández D, Kiessling P, Kus J, Matamoros N, Niehues T, Schmidt S, Schulze I, Borte M. Gardulf A, et al. Among authors: borte m. J Allergy Clin Immunol. 2004 Oct;114(4):936-42. doi: 10.1016/j.jaci.2004.06.053. J Allergy Clin Immunol. 2004. PMID: 15480339
New Frontiers in Subcutaneous Immunoglobulin Treatment.
Jolles S, Stein MR, Longhurst HJ, Borte M, Ritchie B, Sturzenegger MH, Berger M. Jolles S, et al. Among authors: borte m. Biol Ther. 2011 Dec 14;1(1):3. doi: 10.1007/s13554-011-0009-3. eCollection 2011. Biol Ther. 2011. PMID: 24392293 Free PMC article. Review.
A Multi‑Center, Open‑Label, Single‑Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency.
Santamaria M, Neth O, Douglass JA, Krivan G, Kobbe R, Bernatowska E, Grigoriadou S, Bethune C, Chandra A, Horneff G, Borte M, Sonnenschein A, Kralickova P, Ramón SS, Langguth D, Gonzalez-Granado LI, Alsina L, Querolt M, Griffin R, Hames C, Mondou E, Price J, Sanz A, Lin J. Santamaria M, et al. Among authors: borte m. J Clin Immunol. 2022 Apr;42(3):500-511. doi: 10.1007/s10875-021-01181-6. Epub 2022 Jan 1. J Clin Immunol. 2022. PMID: 34973143 Free PMC article.
251 results